Fig. 1

Evolution of composite symptom scores over time of treatment with rupatadine 10 mg or 20 mg, or placebo. Data are expressed as mean change from baseline over 28 days of treatment for (a) T4NSS, or (b) T5SS. Statistical significance was calculated with the Mann–Whitney test. *p < 0.05, **p < 0.01 (rupatadine groups vs placebo); ^‡p < 0.05, ^‡‡p < 0.01 (rupatadine 10 mg vs rupatadine 20 mg). T4NSS Total 4 Nasal Symptom Score, T5SS Total 5 Symptom Score